Viridian Therapeutics (VRDN) Year-over-year earnings per share growth for the last twelve months

Graphic logo of Viridian Corp (VRDN)

Optimizing external research outsourcing stabilizes the growth rate of quarterly earnings per share, where -110.60 represents the latest level. An efficient antibody pipeline reduces long-term risks, impacting cash flow. A narrow profile in treating rare eye pathologies guarantees multi-year monetization of discoveries. The price action of the curve helps investors avoid information gaps between Viridian Therapeutics (VRDN) financial reports.

VRDN: viridiantherapeutics.com Year-over-year earnings per share growth for the last twelve months 07/04/2022 - 11/16/2026

Viridian Therapeutics (VRDN) - metric breakdowns and financial figures

Analysis of all company metrics:Viridian Therapeutics - VRDN
Manufactured product of Viridian Corp

The indicator tracks the daily dynamics of quarterly net earnings per share growth, smoothing out the time gaps between reports. By analyzing the quarterly change in EPS, an investor determines the strength of the fundamental momentum and avoids overpaying for the asset. Growth in this metric confirms the effectiveness of capital management. For Viridian Therapeutics (VRDN), this reflects the successful preparation of production sites. Scaling the output of ophthalmological antibodies should ensure long-term financial growth.

Key competitors

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Bausch Health (BLCO)|Year-over-year earnings per share growth for the last twelve months glaukos.com|Apellis Pharmaceuticals (APLS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth BLTE|OCUL - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth HROW (Harrow Inc)|LENZ Corp (LENZ) - Earnings per share growth in annualized terms for the last twelve months|OCS: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months eyepointpharma.com|KOD: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aldeyra Therapeutics (ALDX)|Year-over-year net earnings per share growth for the last 12 months KALA|IRD - Net earnings per share growth for the trailing year|Year-over-year earnings per share growth for the last twelve months okyopharma.com (OKYO)|Quarterly EPS earnings growth Adverum Biotechnologies Inc. (ADVM)|Year-over-year earnings per share growth for the last twelve months outlooktherapeutics.com OTLK|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)